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AIMS:  Annexin  I  (ANXA1),  a  37kDa  member  of  the
annexin  family  of  Ca2+-binding  and  phospholipid-
binding proteins, is particularly abundant in various
populations  of  peripheral  blood  leukocytes.  Since
this protein modulates the anti-inflammatory actions
of the  steroid hormones, the purpose of this  study
was to investigate the effects of the female sex steroid
hormone, 17b -estradiol (E2b ), on the synthesis and
secretion  of  ANXA1  in  the human CCRF-CEM acute
lymphoblastic leukemia cell line.
Methods: Complementary reverse transcription-poly-
merase chain reaction and Western blot assays were
performed to study the effect of E2b on the expres-
sion of mRNA and protein ANXA1, respectively.
Results and discussion: Treatment of CCRF-CEM cells
with  E2b ,  for  30min,  stimulated  the  synthesis  of
ANXA1 mRNA molecules, and increased the cellular
level  of  ANXA1  protein.  Moreover,  when  the  cells
were  incubated  with  E2b ,  under  the  same  experi-
mental  conditions,  a  significant  increase  in  the
amount  of ANXA1  secreted  from  the  cells  was  also
detected.  ICI  182,780,  a  selective  inhibitor  of  the
intracellular estrogen receptor, had no effect on the
E2b -stimulated  expression  and  externalisation  of
ANXA1. Taken together, these results indicate that E2b
induces de novo synthesis of ANXA1 and stimulates its
secretion  in  the  CCRF-CEM  cell  line,  apparently
through  a  mechanism  independent  of  the  intra-
cellular estrogen receptor.
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Introduction
Annexin I (ANXA1) belongs to the annexin family of
Ca2+-binding and phospholipid-binding proteins that
lack the classic ‘EF-hand’ motif for Ca2+ binding.1 A
growing body of evidence indicates that ANXA1 acts
as  an  endogenous  anti-inflammatory  mediator.
ANXA1  has  been  implicated  in  several  biological
processes, including cell growth and differentiation,
inhibition  of  chemotaxis,  and  release  of  inflamma-
tory mediators, such as eicosanoids2,3 and inflamma-
tory cytokines.4
Human  monocytes  and  polymorphonuclear  neu-
trophils constitutively express the protein ANXA1,1,5
as  well  as  plasma  membrane,  specific  and  Ca2+-
dependent binding  sites for  this  protein.1,2 In  con-
trast  to  what  has  been  described  for  those  cells,
little is known about the capacity of lymphocytes to
synthesise  and  secrete ANXA1.6–8 Interestingly,  the
steroid hormone 17b -estradiol (E2b ) has been repor-
ted  to  have  anti-inflammatory  properties,  which
result,  at  least  in  part,  from  a  direct action of  the
hormone on lymphocytes.9 Among lymphoid cells, T
lymphocytes appear to be the most sensitive to the
effects  of  E2b .10,11 Furthermore,  some  of  the  anti-
inflammatory  effects  of  E2b are  identical  to  those
exerted by ANXA1.12,13 However, the ability of E2b
to induce ANXA1 synthesis either in lymphocytes or
other  cell  types  has  not  been  reported  to  date.
Therefore, the objective of this study  was to inves-
tigate  the  synthesis  and  secretion  of  ANXA1  in
lymphocytes, in response to E2b . For this purpose,
we used the human  acute lymphoblastic leukaemia
cell line CCRF-CEM, which expresses characteristics
of T lymphocytes.14
Materials and methods
Chemicals
Mouse  monoclonal  antibodies  against  ANXA1  and
actin were purchased, respectively, from BAbCO (CA,
USA)  and  Boehringer Mannheim (Carnaxide, Portu-
gal), and the horseradish peroxidase-conjugated goat
anti-mouse  immunoglobulin  was  from  Pierce  (IL,
USA). ICI 182,780 was kindly supplied by AstraZeneca
Biociˆ encia  (Barcarena,  Portugal). All  other  reagents
were from Sigma Chemical Co.
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The  human  T-cell  CCRF-CEM  acute  lymphoblastic
leukemia  cell  line  (ATCC, Rockville, MD, USA) was
maintained in RPMI medium supplemented with 10%
fetal calf serum (FCS), 100 m g/ml of streptomycin and
100U/ml of penicillin, at 37°C, in an atmosphere of
5% CO2/95% air. CCRF-CEM cells (1 ´ 106 cells/ml)
were  plated  in  six-well  culture  dishes  with  RPMI
supplemented with 2.5% FCS and antibiotics, for 14h
prior to all the experiments described.
Cell viability
Viability of the CCRF-CEM cells was always checked
by the trypan blue exclusion and MTT reduction tests
prior to the experiments. Assessment of MTT reduc-
tion  was  made  by  the  colorimetric  assay,  using
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl  tetrazolium
bromide (MTT), as previously described.15
Reverse transcription-polymerase chain
reaction assays
For the reverse transcription-polymerase chain reac-
tion (RT-PCR) assays, CCRF-CEM cells were incubated
in  the  presence  of  or  in  the  absence  of  E2b
(0.01–1 m M), or in E2b (1 m M) + the estrogen antago-
nist  ICI  182,780  (10m M),  for  30min–4h.  After
incubation,  the  cells  were  washed  twice  in  phos-
phate-buffered  saline  (PBS)  with  0.1%  diethyl  pyr-
ocarbonate,  and  the  total  RNA  was  isolated  with
TRIzol.  RT-PCR  was  standardised  by  amplifying  a
410  base  pair  (bp)  sequence  of  ANXA1  mRNA
with  the  primers  59 CAAACTGTGAAGTCATC-
CAAAG39 and  59 TCCTCTCTGTAGACCCTG39 ,  and  a
540bp sequence of the b -actin mRNA (as an internal
control) with the primers 59 GTGGGGCGCCCCAGG-
CACCA39 and 59 CTCCTTAATGTCACGCACGATTTC39 .
The reactions were performed with Ready-to-go RT-
PCR  beads  using  150ng  of  total  RNA  and  the
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FIG. 1. Cell viability of CCRF-CEM cells when incubated in the presence of estrogen antagonists. Cells were incubated in the
absence (control, C) or in the presence of ICI 182,780 (1–25m M) (A), or with tamoxifen citrate (1–10m M) (B). Cell viability was
assessed by the MTT reduction test. The data shown are an average of three independent experiments. Values are mean±SD,
** p < 0.01 as determined by one-way ANOVA with Dunnett’s post test.following program: 42°C for 30min, 95°C for 5min,
20 cycles (95°C for 1min, 55°C for 1min, 72°C for
1min), and 72°C for 5min. The RT-PCR products were
separated in  a  1%  agarose  gel  electrophoresis, and
visualised by ethidium bromide staining.
Western blot analysis
For  immunodetection  of  ANXA1,  CCRF-CEM  cells
were  incubated  with  or  without  E2b (0.01–1 m M),
or  with  E2b (1 m M)  +  ICI  182,780  (10 m M),  for
30min-4h. After incubation, the cells  were washed
by  centrifugation  in  PBS.  The  secreted  ANXA1
bound  to  plasma  membrane  receptors  was  extrac-
ted  by  washing  the  cells,  for  10sec,  in  1 mM  of
ethylenediaminetetraacetic  acid  (EDTA),  as  previ-
ously  described.16 The  supernatant  was  collected
for secreted plasma membrane-bound ANXA1 detec-
tion, and the pelleted cells were washed once again
in PBS to remove all secreted protein contaminant.
Cells  were  then  lysed  in  lysis  buffer  (10 mM  of
Tris–HCl  (pH  7.6),  10%  glycerol,  5 mM  of  b -mer-
captoethanol,  and  the  protease  inhibitor  cocktail)
and  sonicated.  Samples  of  cellular  lysates  (30 m g)
and  the  cell  supernatant  containing  the  secreted
proteins  (2 m g)  were  added  (1:1)  to  denaturating
buffer  (200 mM  of Tris,  200 mM  of  bicine,  8M  of
urea, 4% sodium dodecyl sulfate  (SDS),  10%  b -mer-
captoethanol  and  0.2%  bromophenol  blue),  and
subjected  to  12%  SDS-polyacrylamide  gel  electro-
phoresis. After electrotransferration to a PVDF mem-
brane, ANXA1  was  detected  by  incubation  with  a
mouse anti-ANXA1 monoclonal antibody (2  m g/ml),
followed  by  incubation  with  a  horseradish  perox-
idase-conjugated  goat  anti-mouse  antibody.  The
immunocomplexes were visualised by the enhanced
chemiluminescence  (ECL)  method. To  demonstrate
equivalent total protein loading, the stripping of the
membrane  was  performed  with  stripping  buffer
(100 mM  of  b -mercaptoethanol,  2%  SDS,  62.5 mM
of Tris–HCl  (pH  6.7)  at  55°C,  and  the  membrane
was treated as already indicated using the anti-actin
mouse  monoclonal  antibody  (0.1 m g/ml). The  Pon-
ceau S staining of the PVDF membrane was used to
show equivalent secreted protein loading.
Statistical analysis
Assay data were expressed as mean±SD. Comparison
of data from two treatment groups was made by the
Student’s two-tailed unpaired t-test. When comparison
of  data from  more than two treatment groups  was
required, one-way analysis of variance (ANOVA) with
Dunnett’s  post  test  was  used. A  probability  of  less
than  5%  (i.e.  p <  0.05)  was  taken  as  statistically
significant.
Results
Cell viability
The  cell  viability  was  previously  assessed  prior  to
each the experiment. The viability of CCRF-CEM cells
incubated in the presence of E2b was always >95%
(data  not  shown). When  the  cells  were  incubated
with  the  pure  anti-estrogen  ICI  182,780  at  the
concentrations used in the present work (10m M), the
viability was also > 95%. Concentrations higher than
10 m M of ICI 182,780 caused cell death (Fig. 1A). The
estrogen antagonist tamoxifen citrate, at the concen-
tration of 1 m M, decreased cell viability by more than
18% (Fig.  1B). Therefore, tamoxifen citrate was not
used in the present work.
Effect of E2b on ANXA1 mRNA synthesis in
CCRF-CEM cells
The ability of E2b to induce ANXA1 mRNA synthesis
in  CCRF-CEM cells was studied by  RT-PCR, using  a
specific  pair  of  primers  that  amplify  a  410bp
sequence of ANXA1 mRNA (Fig. 2).
17b -Estradiol upregulates annexin I
Mediators of Inflammation · Vol 10 · 2001 247
FIG. 2. Effect of E2b on ANXA1 mRNA synthesis in CCRF-
CEM cells. Cells were incubated in the absence (control, C)
and in the presence of E2b (1m M) for 30min (A). The bands
were quantified with an image analyser (B). ANXA1 mRNA
was detected by RT-PCR with a pair of primers specific for a
fragment of ANXA1 mRNA. The data shown are an average
of three independent experiments. Values are mean±SD, **
p <  0.01  as  determined  by  Student’s  two-tailed  unpaired
t-test.CCRF-CEM cells incubated in the presence of E2b at
a  concentration  ranging  from  0.01  to  1 m M,  for
30min, showed an increase in ANXA1 mRNA expres-
sion  (data  not  shown).  However,  the  increase was
constant  and  reached  statistical  significance  only
when the cells were treated with 1m M of E2b (120.2
± 6.7  arbitrary units  (AU)  versus  69.6  ± 2.6AU,  in
control; p < 0.01) (Fig. 2). Longer incubation in the
presence of E2b did not change these results (data not
shown).
Co-incubation of CCRF-CEM cells with E2b (1m M)
and the estrogen antagonist ICI 182,780 (10 m M) was
performed  to  investigate  the  role  of  the  estrogen
receptor  (ER)  in  the  effect  of  E2b on  the ANXA1
mRNA  expression  (Fig.  3). The  rise  in  the ANXA1
mRNA level induced by E2b (1 m M), in the presence
or in  the absence of  ICI 182,780  (10 m M)  was not
significantly different (p > 0.05). However, confirming
the  previous  results,  both  E2b (1 m M)  (207.7  ±
25.2AU)  and  E2b (1 m M)  +  ICI  182,780  (10 m M)
(194.1 ± 14.1AU) induced a significant increase of the
control level of ANXA1 mRNA (74.25 ± 2.2AU) (p <
0.01) (Fig. 3B).
Effect of E2b on ANXA1 protein expression and
secretion in CCRF-CEM cells
To test the effect of E2b on ANXA1 protein synthesis
and secretion, CCRF-CEM cells were incubated in the
presence  or  in  the  absence of  different  concentra-
tions  of  E2b (0.01–1 m M). A  significant,  measurable
and constant effect was only observed with 1 m M of
E2b (data not shown). As a consequence, 1 m M of E2b
was  the  concentration used  in  all  the  experiments
performed  to study ANXA1 protein expression  and
secretion.
As  shown  in  Fig.  4,  the  basal  level  of  cellular
ANXA1  was  significantly  decreased  after  30min
(359.1 ± 16.1AU) of incubation with E2b relative to
control untreated cells (488.8 ± 33.6AU; p < 0.01).
After  2h  (518.9  ±  35.1AU)  and  4h  (568.2  ±
13.8AU)  of  incubation  with  E2b ,  the  cellular  con-
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FIG. 3. Effect of E2b and ICI 182,780 on ANXA1 mRNA synthesis in CCRF-CEM cells. Cells were incubated in the absence
(control, C) and in the presence of E2b (1m M), and in E2b (1m M) + ICI 182,780 (10m M) for 30min (A). The bands were quantified
with an image analyser (B). ANXA1 mRNA was detected by RT-PCR with a pair of primers specific for a fragment of ANXA1
mRNA. The data shown are an average of three independent experiments. Values are mean±SD, ** p < 0.01 as determined by
one-way ANOVA with Dunnett’s post test.tent  of  the  protein  was  increased,  reaching  levels
statistically  equivalent  to  the  control  (488.8  ±
33.6AU;  p >  0.05).  Since  cell  viability  was  well
maintained  throughout  the  experiments  (data  not
shown),  the loss in  cellular ANXA1 after  30min  of
exposure  to  E2b is  certainly  due  to  the  specific
secretion  of  the  protein.  In  fact,  the  level  of  the
plasma  membrane-bound  EDTA-extractable  ANXA1
increased from 184.1 ± 29.2AU (control) to 378.8 ±
29.9,  584.3  ±  79.3  and  607.3  ±  47.1AU  in  cells
treated  with  E2b for  30min,  2h  and  4h,  respec-
tively  (p <  0.05,  p  <  0.01  and  p <  0.01)  (Fig.  5).
Taken together, these results indicate that E2b indu-
ces de novo synthesis of ANXA1 and stimulates its
secretion in CCRF-CEM cells.
Co-incubation of CCRF-CEM cells with E2b (1m M)
and the estrogen antagonist ICI 182,780 (10 m M) was
performed  to  investigate  the  role  of  the ER  in  the
effect of E2b on the synthesis and secretion of ANXA1.
ICI 182,780  neither affected the amount of  plasma
membrane-bound ANXA1 in control cells or reversed
the E2b -dependent secretion of ANXA1 in CCRF-CEM
cells (data not shown).
Discussion
Several studies reported in the literature have shown
that  glucocorticoid  hormones  have  a  remarkable
effect on ANXA1 protein expression and secretion in
a variety of in vivo and in vitro systems.1,4,5 But, to
our knowledge, this is the first study demonstrating
that  the  sex  steroid  hormone  E2b stimulates  the
synthesis and the secretion of ANXA1.
Incubating the lymphoblastic CCRF-CEM cells with
E2b (1 m M)  for  30min  resulted  in  an  increased
expression of ANXA1 mRNA (Fig. 2). When the cells
were  incubated  with  this  hormone  for  2h,  the
synthesis of ANXA1 mRNA molecules was followed by
an increase in the cellular content of ANXA1 protein
(Fig. 4). Moreover, treatment of CCRF-CEM cells with
E2b (1 m M) for 30min caused a significant increase in
the  amount  of  ANXA1  bound  to  specific  ANXA1
binding receptors localised in the outer surface of the
plasma membrane of these cells (Fig. 5). These results
are in agreement with those published by Philip et
al.16 They reported that washing the cells in a Ca2+-
free  medium  removes  the  ANXA1  from  the  outer
17b -Estradiol upregulates annexin I
Mediators of Inflammation · Vol 10 · 2001 249
FIG. 4. Effect of E2b on cellular ANXA1 protein expression in CCRF-CEM cells. Cells were incubated in the absence (control, C)
or in the presence of E2b (1m M), for 30min, 2h and 4h. The cellular content of ANXA1 was determined by Western blot analysis
(A), and the bands were quantified with an image analyser (B). Detection of cellular ANXA1 protein was achieved using a
mouse monoclonal anti-ANXA1  antibody. The data shown are an average of three independent experiments. Values are
mean±SD, ** p < 0.01 as determined by one-way ANOVA with Dunnett’s post test.surface of the plasma membrane of the cells, and that
this protein corresponds to the externalised ANXA1.
Based on these findings, our results indicate that E2b
efficiently stimulates ANXA1 secretion.
The  mechanisms  by  which  E2b stimulates  the
synthesis  and  the  secretion  of  ANXA1  are  still
unknown. It is known that E2b exerts its major effects
on  cell  growth,  differentiation  and  function  by
specifically  interacting  with  intracellular  ER.17 The
complex E2b -ER migrates to the nucleus of the cells,
where it binds to estrogen-responsive elements pres-
ent in the genomic DNA. The anti-estrogens compete
with the  hormone (E2b )  for  the estrogen receptor,
giving rise to inactive ligand–receptor complexes.18
For example, ICI 182,780 binds with high affinity to
intracellular ER, inhibiting its dimerisation, and func-
tions as a pure E2b antagonist.19,20
In  this  work,  we  used  ICI  182,780  (10 m M)  to
investigate the involvement of the intracellular ER on
ANXA1  expression  and  secretion  induced  by  E2b
(1 m M).  Our  results  show  that ICI 182,780  did not
inhibit the E2b -induced stimulation of ANXA1 mRNA
expression (Fig. 3). We also observed that ICI 182,780
was without effect on the synthesis and secretion of
ANXA1  protein  induced  by  E2b (data  not  shown).
Taken together, these results  suggest that the intra-
cellular ERs are probably not involved in mediating
the E2b effects reported here. Receptor-independent
mechanisms  have  been  suggested  to  mediate  the
response  of  estrogen  in  different  cell  types,  in  a
manner  dependent  on  the  culture  conditions  and
estrogen concentrations.21 Nanomolar concentrations
of  estrogen  seem to  exert their  effects  by  a  direct
genomic action of the complex estrogen-ER on DNA,
activating  specific  estrogen-responsive  genes,17
whereas micromolar concentrations of this hormone
appear  to  also  activate  other  intracellular  signaling
pathways, like the mitogen-activated protein kinase
cascade.21–23 It is worth noticing that, in our study,
the concentrations of E2b that reproducibly induced
ANXA1  expression  and  secretion are  in  the  micro-
molar  range,  thus  further  supporting  that  the  E2b
effects observed are independent of the ER. Never-
theless, it could be argued that other ER antagonists,
such as tamoxifen citrate, as well as higher concentra-
tions of ICI 182,780 should be used to fully character-
ise the involvement of ER in the E2b -induced respon-
ses. Unfortunately,  we found  that tamoxifen citrate
and  ICI  182,780  are  toxic  to  CCRF-CEM  cells  in
concentrations higher than 1 and 10 m M, respectively
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FIG. 5. Effect of E2b on ANXA1 secretion in CCRF-CEM cells. Cells were incubated in the absence (control, C) or in the presence
of E2b (1m M) for 30min, 2h and 4h (A). The bands were quantified with an image analyser (B). Plasma membrane bound
ANXA1 was obtained after washing the cells with 1 mM EDTA buffer, as described in ‘Materials and methods’. Detection of
plasma membrane bound ANXA1 was achieved using a mouse monoclonal anti-ANXA1 antibody. The data shown are an
average of three independent experiments. values are mean±SD, * p < 0.05 and ** p < 0.01 as determined by one-way ANOVA
with Dunnett’s post test.(Fig. 1), which precluded the performance of those
studies. Thus, we  cannot fully  exclude  the involve-
ment  of  the  ER  in  mediating  E2b -induced  ANXA1
expression  and  secretion, although  it  seems  highly
unlikely.
In summary, the synthesis and secretion of ANXA1
in  CCRF-CEM  cells  in  response  to  E2b (1 m M)  is
consistent with in vivo studies showing that E2b in
physiological concentrations (1pM–100 m M) partici-
pates  in  the  regulation  of  anti-inflammatory
events.9,24,25 Although  the  results  from  our  studies
suggest that E2b acts by an ER-independent pathway,
further studies are being performed to better under-
stand the mechanisms by  which this hormone reg-
ulates  the  expression  of  ANXA1  in  the  lymphoid
lineage.
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